Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial)

BACKGROUND: Osimertinib, a third generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), is active against EGFR-mutant non-small cell lung cancer (NSCLC) resistant to first-/second-generation EGFR-TKIs with the T790M mutation. T790M monitoring in plasma circulating tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Usui, Kazuhiro, Yokoyama, Takuma, Naka, Go, Ishida, Hiroo, Kishi, Kazuma, Uemura, Kohei, Ohashi, Yasuo, Kunitoh, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541116/
https://www.ncbi.nlm.nih.gov/pubmed/30809659
http://dx.doi.org/10.1093/jjco/hyz023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541116/
https://www.ncbi.nlm.nih.gov/pubmed/30809659
http://dx.doi.org/10.1093/jjco/hyz023

Ejemplares similares